Afatinib in advanced squamous cell carcinoma of the lung: Added benefit not proven

August 18, 2016, Institute for Quality and Efficiency in Health Care

Afatinib (trade name: Giotrif) has been approved since April 2016 for the treatment of adults with locally advanced or metastatic non-small cell lung cancer (NSCLC) of squamous histology who have already received chemotherapy. In an early benefit assessment, the German Institute for Quality and Efficiency in Health Care (IQWiG) has now examined whether in these patients this drug offers advantages over the appropriate comparator therapy. According to the findings, an added benefit of afatinib for these patients is not proven.

Requirements for comparator therapy not met

The Federal Joint Committee (G-BA) specified docetaxel or - if no further chemotherapy is indicated for the patients - best supportive care as appropriate . The drug presented no data for this second research question.

For the first research question - i.e. patients who can receive further chemotherapy - the manufacturer cited the study LUX-Lung 8. In this study, however, afatinib was not compared with docetaxel, but with erlotinib. The manufacturer did not sufficiently justify the therapeutic equivalence of these two drugs in the treatment of with . IQWiG therefore concluded that there was no comparison with the appropriate comparator therapy that could be assessed.

Indirect comparison without informative value

In addition, the manufacturer conducted an indirect comparison with erlotinib as common comparator, using the LUX-Lung 8 study on the afatinib side, and the TAILOR study on the docetaxel side. However, the manufacturer did not attempt to derive an added benefit from this comparison. The information on study design and on the participants in the TAILOR study was actually inadequate to assess whether both studies were sufficiently similar. In addition, the dosage of did not exactly comply with the Summary of Product Characteristics, and only results on overall survival were reported under patient-relevant outcomes.

Hence also from the indirect comparison no conclusion on advantages or disadvantages of afatinib could be derived. IQWiG therefore concluded that an added benefit of afatinib in with the appropriate comparator therapy is not proven.

G-BA decides on the extent of added benefit

The dossier assessment is part of the early benefit assessment according to the Act on the Reform of the Market for Medicinal Products (AMNOG) supervised by the G-BA. After publication of the dossier assessment, the G-BA conducts a commenting procedure and makes a final decision on the extent of the added benefit.

An overview of the results of IQWiG's benefit assessment is given by a German-language executive summary. In addition, the Website gesundheitsinformation.de, published by IQWiG, provides easily understandable German-language information.

More English-language information will be available soon (Sections 2.1 to 2.5 of the dossier assessment as well as subsequently published health information on informedhealth.org).

Explore further: Secukinumab in ankylosing spondylitis or psoriatic arthritis: Added benefit not proven

More information: www.iqwig.de/download/A16-22_A … ertung-35a-SGB-V.pdf

Related Stories

Secukinumab in ankylosing spondylitis or psoriatic arthritis: Added benefit not proven

March 18, 2016
Secukinumab (trade name: Cosentyx) has been approved since November 2015 for adults with active ankylosing spondylitis or psoriatic arthritis. For patients with plaque psoriasis, the drug already underwent an early benefit ...

Ospemifene in vulvovaginal atrophy: Added benefit not proven

August 10, 2016
Ospemifene (tradename: Senshio) is approved for the treatment of moderate to severe symptomatic vulvovaginal atrophy (VVA) in post-menopausal women who are not candidates for local vaginal oestrogen therapy. The drug has ...

Idelalisib in second-line treatment for CLL: Added benefit again not proven

July 6, 2016
Already in 2014, the German Institute for Quality and Efficiency in Health Care (IQWiG) examined in an early benefit assessment whether idelalisib offers advantages over the appropriate comparator therapy for patients with ...

Mepolizumab in severe asthma: Added benefit not proven

May 2, 2016
The monoclonal antibody mepolizumab has been approved since the end of 2015 for the treatment of adults with severe refractory eosinophilic asthma. The German Institute for Quality and Efficiency in Health Care (IQWiG) now ...

Necitumumab in NSCLC: Indication of minor added benefit for patients with metastases

July 5, 2016
The monoclonal antibody necitumumab has been approved since February 2016 for the treatment of patients with locally advanced or metastatic epidermal growth factor receptor (EGFR) expressing non-small cell lung cancer (NSCLC) ...

Osimertinib in lung cancer: Added benefit not proven

June 20, 2016
Osimertinib has been approved since February 2016 for the treatment of adult patients with locally advanced or metastatic epidermal growth factor receptor (EGFR) T790M mutation-positive non-small cell lung cancer (NSCLC). ...

Recommended for you

Common use of antipsychotics shown ineffective for delirium in intensive care patients

October 22, 2018
Critically ill patients in intensive care units (ICUs) did not benefit from two antipsychotic drugs used to treat delirium, according to a large clinical trial funded by the National Institute on Aging, part of the National ...

Medicating distress: Risky sedative prescriptions for older adults vary widely

October 18, 2018
Despite years of warnings that older adults shouldn't take sedative drugs that put them at risk of injury and death, a new study reveals how many primary care doctors are still prescribing them, how often, and exactly where.

Medical management of opioid-induced constipation differs from other forms of condition

October 17, 2018
Traditional laxatives are recommended as first-line agents to treat patients with a confirmed diagnosis of opioid-induced constipation (OIC), according to a new guideline from the American Gastroenterological Association ...

Research assesses geographic distribution of new antibiotics following market introduction

October 16, 2018
There is a growing need for new antibiotics to help combat the looming threat of antimicrobial resistance. According to a new study conducted by researchers at the Center for Disease Dynamics, Economics & Policy (CDDEP) with ...

Health insurer policies may discourage use of non-opioid alternatives for lower back pain

October 5, 2018
Public and private health insurance policies in the U.S. are missing important opportunities to encourage the use of physical therapy, psychological counseling and other non-drug alternatives to opioid medication for treating ...

Opioid overdoses, depression linked

October 3, 2018
The link between mental health disorders and substance abuse is well-documented. Nearly one in 12 adults in the U.S is depressed, and opioid-related deaths are skyrocketing. As these numbers continue to climb, some mental ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.